EMT inhibitor-1 is an inhibitor of of Hippo , TGF-β , and Wnt signaling pathways with antitumor activities. In Vitro EMT inhibitor-1 (C19) (0-10μM; 24 hours) is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities, inhibiting cancer cell migration, proliferation, and resistance to doxorubicin in vitro. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo EMT inhibitor-1 (C19) (intraperitoneal injection; 5-20 mg/kg) exerts strong antitumor activity in a mouse tumor model. Mechanistically, EMT inhibitor-1 induces GSK3-β–mediated degradation of the Hippo transducer TAZ, through activation of the Hippo kinases Mst/Lats and the tumor suppressor kinase AMPK upstream of the degradation complex .C19 is dissolved in the vehicle solution (100 μL of DMEM containing 5% dimethyl sulfoxide). MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:Hippo, TGF-β, Wnt
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
EMT inhibitor-1
CAS number：1638526-21-2(DMSO) molecular formula：C12H12Cl2N2O2S
overview
compound introduction
Specs
| Chinese alias | EMT抑制剂-1 | ||
| English alias | - | ||
| CAS number | 1638526-21-2(DMSO) | molecular formula | C12H12Cl2N2O2S |
| molecular weight | 319.21 g/mol | Exact mass | 10mM in DMSO |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
